Under the deal – which will see Recipharm make commercial supplies of the adrenal insufficiency drug Plenadren – ViroPharma will invest in new tablet manufacturing and active pharmaceutical ingredient (API) coating technology to be installed at the CDMO’s plant in Arsta, Stockholm
The agreement follows Recipharm’s completion of a scale-up contract with original Plenadren developer Sweden-based DuoCort, which was acquired by ViroPharma in November for an upfront payment of $33m (€25m).
Helene Fehrm, General Manager at Recipharm Stockholm told Outsourcing-pharma.com that: “we will be able to use the technology for other customers” although the US drugmaker “retains its status as a customer with the highest priority.”